Gary A Lyons - Net Worth and Insider Trading

Gary A Lyons Net Worth

The estimated net worth of Gary A Lyons is at least $16 Million dollars as of 2024-11-29. Gary A Lyons is the Director of Neurocrine Biosciences Inc and owns about 119,047 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $15 Million. Gary A Lyons is the Director of Travere Therapeutics Inc and owns about 51,000 shares of Travere Therapeutics Inc (TVTX) stock worth over $953,700. Gary A Lyons is also the Director of Fresh Tracks Therapeutics Inc and owns about 25 shares of Fresh Tracks Therapeutics Inc (FRTX) stock worth over $18. Details can be seen in Gary A Lyons's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gary A Lyons has not made any transactions after 2024-10-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Gary A Lyons

Gary A Lyons Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gary A Lyons owns 10 companies in total, including Fresh Tracks Therapeutics Inc (FRTX) , Eledon Pharmaceuticals Inc (ELDN) , and Neurocrine Biosciences Inc (NBIX) among others .

Click here to see the complete history of Gary A Lyons’s form 4 insider trades.

Insider Ownership Summary of Gary A Lyons

Ticker	Comapny	Transaction Date	Type of Owner
FRTX	Fresh Tracks Therapeutics Inc	2021-06-14	director
ELDN	Eledon Pharmaceuticals Inc	2017-05-10	director
NBIX	Neurocrine Biosciences Inc	2024-08-13	director & President and CEO
		2022-05-20	director
		2024-10-04	director
		2013-10-07	director
		2012-08-11	director
		2012-06-07	director
		2011-07-11	director
		2008-08-13	director

Gary A Lyons Latest Holdings Summary

Gary A Lyons currently owns a total of 3 stocks. Among these stocks, Gary A Lyons owns 119,047 shares of Neurocrine Biosciences Inc (NBIX) as of August 13, 2024, with a value of $15 Million and a weighting of 94.05%. Gary A Lyons owns 51,000 shares of Travere Therapeutics Inc (TVTX) as of October 4, 2024, with a value of $953,700 and a weighting of 5.95%. Gary A Lyons also owns 25 shares of Fresh Tracks Therapeutics Inc (FRTX) as of December 5, 2016, with a value of $18 and a weighting of 0%.

Latest Holdings of Gary A Lyons

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
NBIX	Neurocrine Biosciences Inc	2024-08-13	119,047	126.59	15,070,160
TVTX	Travere Therapeutics Inc	2024-10-04	51,000	18.70	953,700
FRTX	Fresh Tracks Therapeutics Inc	2016-12-05	25	0.72	18

Holding Weightings of Gary A Lyons

Gary A Lyons Form 4 Trading Tracker

According to the SEC Form 4 filings, Gary A Lyons has made a total of 13 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Neurocrine Biosciences Inc is the sale of 11,570 shares on August 13, 2024, which brought Gary A Lyons around $2 Million.

According to the SEC Form 4 filings, Gary A Lyons has made a total of 1 transactions in Travere Therapeutics Inc (TVTX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Travere Therapeutics Inc is the sale of 40,000 shares on October 4, 2024, which brought Gary A Lyons around $589,200.

According to the SEC Form 4 filings, Gary A Lyons has made a total of 0 transactions in Fresh Tracks Therapeutics Inc (FRTX) over the past 5 years. The most-recent trade in Fresh Tracks Therapeutics Inc is the sale of 22 shares on December 5, 2016, which brought Gary A Lyons around $16,279.

Insider Trading History of Gary A Lyons

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gary A Lyons Trading Performance

GuruFocus tracks the stock performance after each of Gary A Lyons's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gary A Lyons is -17.48%. GuruFocus also compares Gary A Lyons's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gary A Lyons within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Gary A Lyons's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Gary A Lyons

Average Return

Average return per transaction

Outperforming Transactions

1 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	0.91
Relative Return to S&P 500(%)	1.66

Gary A Lyons Ownership Network

Ownership Network List of Gary A Lyons

No Data

Ownership Network Relation of Gary A Lyons

Gary A Lyons Owned Company Details

What does Fresh Tracks Therapeutics Inc do?

Who are the key executives at Fresh Tracks Therapeutics Inc?

Gary A Lyons is the director of Fresh Tracks Therapeutics Inc. Other key executives at Fresh Tracks Therapeutics Inc include Chief Medical Officer Monica E. Luchi , director & CHAIRMAN OF THE BOARD Reginald L Hardy , and General Counsel and CCO David R. Mcavoy .

Fresh Tracks Therapeutics Inc (FRTX) Insider Trades Summary

Over the past 18 months, Gary A Lyons made no insider transaction in Fresh Tracks Therapeutics Inc (FRTX). Other recent insider transactions involving Fresh Tracks Therapeutics Inc (FRTX) include a net sale of 110 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of Fresh Tracks Therapeutics Inc (FRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 110 shares of Fresh Tracks Therapeutics Inc (FRTX) were sold and 1,086,412 shares were bought by its insiders, resulting in a net purchase of 1,086,302 shares.

Fresh Tracks Therapeutics Inc (FRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fresh Tracks Therapeutics Inc Insider Transactions

No Available Data

What does Eledon Pharmaceuticals Inc do?

Who are the key executives at Eledon Pharmaceuticals Inc?

Gary A Lyons is the director of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .

Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eledon Pharmaceuticals Inc Insider Transactions

No Available Data

What does Neurocrine Biosciences Inc do?

Who are the key executives at Neurocrine Biosciences Inc?

Gary A Lyons is the director & President and CEO of Neurocrine Biosciences Inc. Other key executives at Neurocrine Biosciences Inc include Chief Corp. Affairs Officer David W. Boyer , Chief Regulatory Officer Ingrid Delaet , and Chief Financial Officer Matt Abernethy .

Neurocrine Biosciences Inc (NBIX) Insider Trades Summary

Over the past 18 months, Gary A Lyons made 7 insider transaction in Neurocrine Biosciences Inc (NBIX) with a net sale of 50,000. Other recent insider transactions involving Neurocrine Biosciences Inc (NBIX) include a net sale of 32,776 shares made by Ingrid Delaet , a net sale of 58,181 shares made by Darin Lippoldt , and a net sale of 55,568 shares made by Julie Cooke .

In summary, during the past 3 months, insiders sold 4,756 shares of Neurocrine Biosciences Inc (NBIX) in total and bought 0 shares, with a net sale of 4,756 shares. During the past 18 months, 993,959 shares of Neurocrine Biosciences Inc (NBIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 993,959 shares.

Neurocrine Biosciences Inc (NBIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neurocrine Biosciences Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Gary A Lyons is the director of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Gary A Lyons made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Travere Therapeutics Inc do?

Who are the key executives at Travere Therapeutics Inc?

Gary A Lyons is the director of Travere Therapeutics Inc. Other key executives at Travere Therapeutics Inc include VP & Corp Controller and CAO Sandra Calvin , Chief Medical Officer Jula Inrig , and director & Chief Executive Officer Eric M Dube .

Travere Therapeutics Inc (TVTX) Insider Trades Summary

Over the past 18 months, Gary A Lyons made 1 insider transaction in Travere Therapeutics Inc (TVTX) with a net sale of 40,000. Other recent insider transactions involving Travere Therapeutics Inc (TVTX) include a net sale of 4,368 shares made by Christopher R. Cline , a net sale of 33,453 shares made by Eric M Dube , and a net sale of 8,264 shares made by Elizabeth E Reed .

In summary, during the past 3 months, insiders sold 130,059 shares of Travere Therapeutics Inc (TVTX) in total and bought 0 shares, with a net sale of 130,059 shares. During the past 18 months, 159,574 shares of Travere Therapeutics Inc (TVTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 159,574 shares.

Travere Therapeutics Inc (TVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Travere Therapeutics Inc Insider Transactions

No Available Data

What does Plus Therapeutics Inc do?

Who are the key executives at Plus Therapeutics Inc?

Gary A Lyons is the director of Plus Therapeutics Inc. Other key executives at Plus Therapeutics Inc include President Marc H Hedrick , Chief Financial Officer Sims Andrew John Hugh Macintyre , and CHIEF MEDICAL OFFICER Norman D. Lafrance .

Plus Therapeutics Inc (PSTV) Insider Trades Summary

Over the past 18 months, Gary A Lyons made no insider transaction in Plus Therapeutics Inc (PSTV). Other recent insider transactions involving Plus Therapeutics Inc (PSTV) include a net purchase of 28,761 shares made by Robert P Lenk , a net purchase of 22,797 shares made by Howard Clowes , and a net purchase of 44,755 shares made by Greg Petersen .

In summary, during the past 3 months, insiders sold 0 shares of Plus Therapeutics Inc (PSTV) in total and bought 39,883 shares, with a net purchase of 39,883 shares. During the past 18 months, 2,068 shares of Plus Therapeutics Inc (PSTV) were sold and 140,755 shares were bought by its insiders, resulting in a net purchase of 138,687 shares.

Plus Therapeutics Inc (PSTV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Plus Therapeutics Inc Insider Transactions

No Available Data

What does Humanigen Inc do?

Who are the key executives at Humanigen Inc?

Gary A Lyons is the director of Humanigen Inc. Other key executives at Humanigen Inc include 10 percent owner Dale Chappell , Chief Medical Officer Adrian Kilcoyne , and Chief Commercial Officer Edward P. Jordan .

Humanigen Inc (HGENQ) Insider Trades Summary

Over the past 18 months, Gary A Lyons made no insider transaction in Humanigen Inc (HGENQ). Other recent insider transactions involving Humanigen Inc (HGENQ) include a net sale of 386,350 shares made by Dale Chappell ,

In summary, during the past 3 months, insiders sold 0 shares of Humanigen Inc (HGENQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 386,350 shares of Humanigen Inc (HGENQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 386,350 shares.

Humanigen Inc (HGENQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Humanigen Inc Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Gary A Lyons is the director of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Poniard Pharmaceuticals Inc do?

Who are the key executives at Poniard Pharmaceuticals Inc?

Gary A Lyons is the director of Poniard Pharmaceuticals Inc. Other key executives at Poniard Pharmaceuticals Inc include President & CMO Michael S Perry , director & Chief Executive Officer Ron Martell , and director & 10 percent owner Simon Nicholas J Iii .

Poniard Pharmaceuticals Inc (PARD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Poniard Pharmaceuticals Inc (PARD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Poniard Pharmaceuticals Inc (PARD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Poniard Pharmaceuticals Inc (PARD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Poniard Pharmaceuticals Inc Insider Transactions

No Available Data

What does PDL BioPharma Inc do?

Who are the key executives at PDL BioPharma Inc?

Gary A Lyons is the director of PDL BioPharma Inc. Other key executives at PDL BioPharma Inc include President and CEO Dominique Monnet , VP & Gen. Counsel & Secretary Christopher Lewis Stone , and VP Finance & CAO and Acting CFO Edward Imbrogno .

PDL BioPharma Inc (PDLI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PDL BioPharma Inc (PDLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PDL BioPharma Inc (PDLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PDL BioPharma Inc (PDLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

PDL BioPharma Inc Insider Transactions

No Available Data

Gary A Lyons Mailing Address

Above is the net worth, insider trading, and ownership report for Gary A Lyons. You might contact Gary A Lyons via mailing address: 12790 El Camino Real, C/o Neurocrine Biosciences, San Diego Ca 92130.

Discussions on Gary A Lyons

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.